Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Le Moine JG, Fiestas Navarrete L, Katumba K, Launois R. Psychometric validation of the 14 items chronic venous insufficiency quality of life questionnaire (CIVIQ-14): confirmatory factor analysis. Eur J Vasc Endovasc Surg. 2016 Feb;51(2):268-74. doi: 10.1016/j.ejvs.2015.08.020.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Finkelstein EA, Kosa KM. Use of incentives to motivate healthy behaviors among employees. Gender issues. 2003 Jun;21(3):50-9. doi: 10.1007/s12147-003-0005-0